Farbod Sedaghat-Hamedani1,2, Elham Kayvanpour1,2, Oguz Firat Tugrul1,2, Alan Lai1, Ali Amr1,2, Jan Haas1,2, Tanja Proctor3, Philipp Ehlermann1, Katrin Jensen3, Hugo A Katus1,2, Benjamin Meder4,5. 1. Institute for Cardiomyopathy, Department of Medicine III, University of Heidelberg, INF 410, 69120, Heidelberg, Germany. 2. DZHK (German Centre for Cardiovascular Research), Berlin, Germany. 3. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany. 4. Institute for Cardiomyopathy, Department of Medicine III, University of Heidelberg, INF 410, 69120, Heidelberg, Germany. Benjamin.Meder@med.uni-heidelberg.de. 5. DZHK (German Centre for Cardiovascular Research), Berlin, Germany. Benjamin.Meder@med.uni-heidelberg.de.
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which goes along with increased risk for sudden cardiac death (SCD). Despite the knowledge about the different causal genes, the relationship between individual genotypes and phenotypes is incomplete. METHODS AND RESULTS: We retrieved PubMed/Medline literatures on genotype-phenotype associations in patients with HCM and mutations in MYBPC3, MYH7, TNNT2, and TNNI3. Altogether, 51 studies with 7675 HCM patients were included in our meta-analysis. The average frequency of mutations in MYBPC3 (20%) and MYH7 (14%) was higher than TNNT2 and TNNI3 (2% each). The mean age of HCM onset for MYH7 mutation positive patients was the beginning of the fourth decade, significantly earlier than patients without sarcomeric mutations. A high male proportion was observed in TNNT2 (69%), MYBPC3 (62%) and mutation negative group (64%). Cardiac conduction disease, ventricular arrhythmia and heart transplantation (HTx) rate were higher in HCM patients with MYH7 mutations in comparison to MYBPC3 (p < 0.05). Furthermore, SCD was significantly higher in patients with sarcomeric mutations (p < 0.01). CONCLUSION: A pooled dataset and a comprehensive genotype-phenotype analysis show that the age at disease onset of HCM patients with MYH7 is earlier and leads to a more severe phenotype than in patient without such mutations. Furthermore, patients with sarcomeric mutations are more susceptible to SCD. The present study further supports the clinical interpretation of sarcomeric mutations in HCM patients.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which goes along with increased risk for sudden cardiac death (SCD). Despite the knowledge about the different causal genes, the relationship between individual genotypes and phenotypes is incomplete. METHODS AND RESULTS: We retrieved PubMed/Medline literatures on genotype-phenotype associations in patients with HCM and mutations in MYBPC3, MYH7, TNNT2, and TNNI3. Altogether, 51 studies with 7675 HCM patients were included in our meta-analysis. The average frequency of mutations in MYBPC3 (20%) and MYH7 (14%) was higher than TNNT2 and TNNI3 (2% each). The mean age of HCM onset for MYH7 mutation positive patients was the beginning of the fourth decade, significantly earlier than patients without sarcomeric mutations. A high male proportion was observed in TNNT2 (69%), MYBPC3 (62%) and mutation negative group (64%). Cardiac conduction disease, ventricular arrhythmia and heart transplantation (HTx) rate were higher in HCM patients with MYH7 mutations in comparison to MYBPC3 (p < 0.05). Furthermore, SCD was significantly higher in patients with sarcomeric mutations (p < 0.01). CONCLUSION: A pooled dataset and a comprehensive genotype-phenotype analysis show that the age at disease onset of HCM patients with MYH7 is earlier and leads to a more severe phenotype than in patient without such mutations. Furthermore, patients with sarcomeric mutations are more susceptible to SCD. The present study further supports the clinical interpretation of sarcomeric mutations in HCM patients.
Authors: Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman Journal: J Am Coll Cardiol Date: 2004-11-02 Impact factor: 24.094
Authors: Sara L Van Driest; Erik G Ellsworth; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman Journal: Circulation Date: 2003-07-14 Impact factor: 29.690
Authors: Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann Journal: J Clin Invest Date: 2008-11-20 Impact factor: 14.808
Authors: Ali Pedram; Mahnaz Razandi; Ramesh Narayanan; James T Dalton; Timothy A McKinsey; Ellis R Levin Journal: Mol Biol Cell Date: 2013-10-23 Impact factor: 4.138
Authors: Hanna J Tadros; Chelsea S Life; Gustavo Garcia; Elisa Pirozzi; Edward G Jones; Susmita Datta; Michelle S Parvatiyar; P Bryant Chase; Hugh D Allen; Jeffrey J Kim; Jose R Pinto; Andrew P Landstrom Journal: J Mol Cell Cardiol Date: 2020-04-09 Impact factor: 5.000
Authors: Elham Kayvanpour; Farbod Sedaghat-Hamedani; Weng-Tein Gi; Oguz Firat Tugrul; Ali Amr; Jan Haas; Feng Zhu; Philipp Ehlermann; Lorenz Uhlmann; Hugo A Katus; Benjamin Meder Journal: Clin Res Cardiol Date: 2019-04-12 Impact factor: 5.460
Authors: Victoria James; Zubair A Nizamudeen; Daniel Lea; Tania Dottorini; Terri L Holmes; Benjamin B Johnson; Kenton P Arkill; Chris Denning; James G W Smith Journal: Stem Cells Dev Date: 2021-12-15 Impact factor: 3.272
Authors: Sahar Isa Da'as; Waseem Hasan; Rola Salem; Nadine Younes; Doua Abdelrahman; Iman A Mohamed; Arwa Aldaalis; Ramzi Temanni; Lisa Sara Mathew; Stephan Lorenz; Magdi Yacoub; Michail Nomikos; Gheyath K Nasrallah; Khalid A Fakhro Journal: Int J Mol Sci Date: 2022-08-09 Impact factor: 6.208